EP3848022B1 - A therapeutic agent for use in the treatment of infections - Google Patents
A therapeutic agent for use in the treatment of infections Download PDFInfo
- Publication number
- EP3848022B1 EP3848022B1 EP20215977.8A EP20215977A EP3848022B1 EP 3848022 B1 EP3848022 B1 EP 3848022B1 EP 20215977 A EP20215977 A EP 20215977A EP 3848022 B1 EP3848022 B1 EP 3848022B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapeutic agent
- nano
- micro
- particles
- donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims description 33
- 229940124597 therapeutic agent Drugs 0.000 title claims description 25
- 208000015181 infectious disease Diseases 0.000 title claims description 17
- 239000000126 substance Substances 0.000 claims description 46
- 239000002105 nanoparticle Substances 0.000 claims description 41
- 239000011859 microparticle Substances 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 38
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 33
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 32
- 239000002243 precursor Substances 0.000 claims description 30
- 239000000969 carrier Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 19
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 claims description 18
- 229940045872 sodium percarbonate Drugs 0.000 claims description 18
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 17
- 238000002145 thermally induced phase separation Methods 0.000 claims description 13
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 11
- FRPJTGXMTIIFIT-UHFFFAOYSA-N tetraacetylethylenediamine Chemical compound CC(=O)C(N)(C(C)=O)C(N)(C(C)=O)C(C)=O FRPJTGXMTIIFIT-UHFFFAOYSA-N 0.000 claims description 11
- -1 buckyballs Substances 0.000 claims description 10
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000011065 in-situ storage Methods 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 claims description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 3
- 229920002988 biodegradable polymer Polymers 0.000 claims description 3
- 239000004621 biodegradable polymer Substances 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 229960001922 sodium perborate Drugs 0.000 claims description 3
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 3
- 239000004160 Ammonium persulphate Substances 0.000 claims description 2
- 235000019395 ammonium persulphate Nutrition 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- BHDAXLOEFWJKTL-UHFFFAOYSA-L dipotassium;carboxylatooxy carbonate Chemical compound [K+].[K+].[O-]C(=O)OOC([O-])=O BHDAXLOEFWJKTL-UHFFFAOYSA-L 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 229910021392 nanocarbon Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000011068 loading method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- VPVSTMAPERLKKM-UHFFFAOYSA-N glycoluril Chemical compound N1C(=O)NC2NC(=O)NC21 VPVSTMAPERLKKM-UHFFFAOYSA-N 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical class O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- GMLREHXYJDLZOU-LEPYJNQMSA-N 3-Acetylmorphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GMLREHXYJDLZOU-LEPYJNQMSA-N 0.000 description 1
- SKORSNZZDZSCKK-UHFFFAOYSA-N C(C)(=O)NC(N(C(C)=O)C(C)=O)=O Chemical compound C(C)(=O)NC(N(C(C)=O)C(C)=O)=O SKORSNZZDZSCKK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 102100022258 Disks large homolog 5 Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101100063489 Homo sapiens DLG5 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- QISSLHPKTCLLDL-UHFFFAOYSA-N N-Acetylcaprolactam Chemical compound CC(=O)N1CCCCCC1=O QISSLHPKTCLLDL-UHFFFAOYSA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ZJRXSAYFZMGQFP-UHFFFAOYSA-N barium peroxide Chemical compound [Ba+2].[O-][O-] ZJRXSAYFZMGQFP-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000012899 de-mixing Methods 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001976 hemiacetal group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HPGPEWYJWRWDTP-UHFFFAOYSA-N lithium peroxide Chemical compound [Li+].[Li+].[O-][O-] HPGPEWYJWRWDTP-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- UJQLDFMZDSDZEY-UHFFFAOYSA-N n-(acetylcarbamoyl)acetamide Chemical compound CC(=O)NC(=O)NC(C)=O UJQLDFMZDSDZEY-UHFFFAOYSA-N 0.000 description 1
- GKRZNOGGALENQJ-UHFFFAOYSA-N n-carbamoylacetamide Chemical compound CC(=O)NC(N)=O GKRZNOGGALENQJ-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 150000002976 peresters Chemical class 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005086 tooth mineralization Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a micro- or nano-scale therapeutic agent for use in the treatment of infections of humans or animals.
- Such an infection may be a systemic or a topical infection.
- Antibiotic resistance particularly the emergence of widespread multiple drug resistant infections, poses a catastrophic risk to human health and involves substantial costs. Novel approaches to combat infection are therefore urgently required.
- WO2010/134827 discloses a medicament comprising an oxygen generating system for use in a primarily in a low oxygen environment, specifically the mammary gland of an animal such as a dairy cow suffering from mastitis.
- the medicament comprises particles of an oxygen source that is adapted to provide a slow release of peroxide over an extended period by coating of the active compound in a protective sheet, for example by coating sodium percarbonate with ethyl cellulose.
- US2006/0088498 discloses an antimicrobial oxidizing agent in the form of a complex particle with a core and a reactor wall with pores that forms a reactor space containing the core.
- the core comprises a reactant for producing an oxidizer when contacted by a solvent that has penetrated the reactor space through the pores.
- the released oxidizer then leaves the particle through the pores.
- One use of these particles is to reduce the microbe level in the digestive tract of mammals, specifically a farm animal prior to slaughter.
- WO97/07777 discloses an oral care composition
- a nonenzymic, water soluble hydrogen peroxide precursor that is capable of rapidly releasing hydrogen peroxide upon contact with water.
- the composition comprises particle of an alkali percarbonate encapsulated by a non-hydroscopic material.
- compositions, products and methods useful for bone and tooth mineralization comprise polymer microcapsules containing aqueous salt solutions.
- the shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention.
- the microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization.
- Bone products include cements, scaffolds and bioactive glass.
- Dental products include pastes, gels, rinses and many other dental materials.
- US 6 979 467 B1 discloses a microcapsule having a mean diameter of from about 0.1 to about 5 mm, a membrane and a matrix containing at least one active principle wherein the microcapsule is the product of the process comprising the steps of (a) forming an aqueous matrix by heating an aqueous solution comprised of a gel former, an anionic polymer selected from the group consisting of a salt of alginic acid and an anionic chitosan derivative and active principle; (b) forming a dispersed matrix by adding the aqueous matrix in an oil phase; (c) contacting the dispersed matrix with an aqueous solution of chitosan.
- a nano- or micro-scale therapeutic agent for use in the treatment of an infection of a human or animal comprising micro- and/or nano-particle carriers loaded singly or in combination with one or more inert precursor chemicals comprising a peroxygen donor and an acetyl donor, the carriers encapsulating the precursor chemical or chemicals which in situ at the site of an infection are activated by the physiological milieu such that the peroxygen donor forms hydrogen peroxide and the acetyl donor reacts with the hydrogen peroxide to produce a mixture of peracetic acid and hydrogen peroxide, and characterised in that the particle carriers are comprised of a biodegradable polymer.
- the precursor chemical or chemicals form an oxidative biocide on activation.
- Highly oxidative molecules exert a powerful biocidal effect on microorganisms by inflicting massive and widely disseminated damage to the bacterial cell owing to the high energy transfer capability of these molecules. Therefore resistance to these chemicals is rare. Examples of such molecules would be ozone, hypochlorous acid, sodium hypochlorite or hypobromite, chlorine dioxide, peracids such as peracetic acid and hydrogen peroxide. It is not generally practical to use these powerful chemicals for therapeutic purposes but when the encapsulated precursor chemical or chemicals are delivered in micro- and/or nano-particles directly to the target infecting organism production of these chemicals does not occur until the precursor chemical or chemicals are activated in situ at the site of an infection, for example by contact with body fluids.
- the precursor chemical or chemicals comprise one or more peroxygen donors that on release are activated to form hydrogen peroxide.
- release of the precursor chemical or chemicals occurs when the carrier bursts, degrades or changes its porosity in situ, which may be within or, in the case of a topical use, on the body of the human or animal host.
- the carrier degrades via hydrolysis over time to provide a controlled release of the precursor chemical or chemicals.
- micro- and/or nano-particle carriers for use in the present invention are micelles, dendrimers, buckyballs, liposomes, ethosomes, mesoporous silica and nano-carbon tubes, all of which are capable of encapsulating other chemicals.
- the carrier is in the form of micro- and/or nano-particles that have been manufactured using a thermally induced phase separation (TIPS) process.
- TIPS thermally induced phase separation
- the carrier is biodegradable within the body of the host to produce harmless by-products
- the carrier is comprised of a biodegradable polymer such as poly(lactic-co-glycolic acid) (PLGA) that can be used to produce micro- and/or nano-particles encapsulating the precursor chemicals by a TIPS process.
- PLGA poly(lactic-co-glycolic acid)
- PLGA is a copolymer that is synthesized by means of ring-opening copolymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid. It undergoes hydrolysis in vivo to produce the original monomers, lactic acid and glycolic acid, which under normal physiological conditions are by-products of various metabolic pathways in the body. Hence, there is minimal systemic toxicity associated with using PLGA for the purpose of the present invention.
- the precursor chemicals also comprise one or more acetyl donors that on release react with the hydrogen peroxide produced by the peroxygen donor to produce a mixture of peracetic acid and hydrogen peroxide.
- the acetyl donor or donors may be encapsulated within the same carrier particles as the peroxygen donor.
- the therapeutic agent of the invention comprises micro- and/or nano-particle carriers wherein at least a proportion of them each encapsulate both a peroxygen donor and an acetyl donor.
- the acetyl donor is encapsulated within its own micro- and/or nano-particle carriers and the therapeutic agent of the invention comprises a combination of micro- and/or nano-particle carriers that individually encapsulate either the peroxygen donor or donors or the acetyl donor or donors.
- Hydrogen peroxide is widely used in endodontics, in the treatment of periodontitis and as an antiseptic for wounds and mucous membranes.
- Dilute solutions of hypochlorous acid have been advocated for topical disinfection and peracetic acid has been widely used in dairy hygiene as a pre- and post- milking teat disinfectant.
- delivering these highly active agents to the site of more serious deep-seated infections in a controlled, safe and effective manner is largely impractical using conventional methods.
- the present invention overcomes this problem by encapsulating the precursor chemicals in a carrier whereby the antimicrobial agent is only created after the carrier has reached the target and released the precursor chemicals, which are then activated on contact with the target by the physiological milieu, for example by contact with body fluids.
- an inert precursor chemical that can be activated in situ overcomes problems of stability and safety for the active antimicrobial agent.
- a combination of a peroxygen donor with an acetyl donor is used to produce dynamic equilibrium mixtures of hydrogen peroxide and peracetic acid.
- the peroxygen donor preferably comprises any or a combination of the chemicals in the following List A.
- the acetyl donor preferably comprises any or a combination of the chemicals in the following List B.
- peroxygen and acetyl donors are dependent on the physiological milieu to be encountered during use of the therapeutic agent. Those that degrade to produce substances that are either naturally occurring or well tolerated within the body being preferred for in vivo use but others may be appropriate for use externally, for example in the topical treatment of skin infections or for use within a void, fissure or lumen.
- the carrier may comprise micro-particles, nano-particles or a mixture of the two.
- micro-particles are particles of any shape with dimensions in the 1 ⁇ 10 -7 m and 1 ⁇ 10 -4 m range
- nano-particles are particles of any shape with dimensions in the 1 ⁇ 10 -9 m to 1 ⁇ 10 -7 m range.
- Particle size and size distribution are the most important characteristics of micro- and nano-particle systems. They determine the in vivo distribution, biological fate, toxicity and the targeting ability of the carrier. In addition, they can also influence the drug loading, drug release and stability of the carrier.
- Nano-particles of sub-micron size have a number of advantages over micro-particles as drug carriers as they have a relatively higher intracellular uptake compared to micro-particles and are available to a wider range of biological targets owing to their small size and relative mobility.
- micro-particles may be selected and prove more advantageous for use than nano-particles.
- Poly(lactic-co-glycolic acid) (PLGA) - based particles can be produced over a size range from around 20 ⁇ 10 -3 ⁇ m diameter up to micron sizes.
- the production of such particles is known and described, for example, in WO2008/155558 .
- the method of manufacture of these particles can be used to manipulate their properties such as porosity, payload efficiency and drug release profile. This makes them particularly suited to being the carrier in this invention. Loading of these particles with the precursor chemical can be achieved by known techniques either during the particle fabrication process or afterwards.
- therapeutic agents in accordance with the present invention are produced from PLGA solutions containing the active precursor chemicals by a thermally induced phase separation (TIPS) process.
- TIPS thermally induced phase separation
- the TIPS process begins with production of a PLGA solution at a high temperature in order to generate a homogenous solution.
- the precursor chemical is dissolved in a suitable solvent and is then blended into the PLGA solution.
- the removal of thermal energy by rapid cooling below a biomodal solubility curve using another immiscible cooling liquid induces the phase de-mixing of the homogenous PLGA solution into a multi-phase system containing a PLGA-rich phase and PLGA-lean phase.
- the phase separated PLGA solution is subsequently treated by freeze-drying to remove the solvents, generating the micro- and/or nano-particles of the invention.
- poly(DL-lactide-co-glycolide) for example that sold under the registered trade mark PURASORB ® PDLG IV o.68dl/g by Corbion Group Netherlands BV
- PURASORB ® PDLG IV o.68dl/g by Corbion Group Netherlands BV
- the sodium percarbonate was dissolved in ultrapure water at 100 mg/ml by vortexing and then by being allowed to stand for 24 hours. Thereafter, 833 ⁇ l of the sodium percarbonate solution was added to 7.5 ml of the PLGA solution in a capped 10 ml glass vial before mixing by vortexing.
- TIPS micro- and nano-particles were then prepared using a conventional microencapsulator, for example an Encapsulator VAR-D unit as manufactured by Nisco Engineering AG.
- the particles produced were collected in liquid nitrogen before being transferred to a freeze-drier for lyophilisation.
- the resulting particles are as shown in Figs. 1 and 2 .
- the aforesaid methods produced micro- and nano-particles with a loading concentration of 278 mg of the relevant precursor chemical per g PLGA . It is expected that higher concentrations up to approximately double this amount are also achievable if necessary.
- the micro- and nano-particles produced have a rugose and porous surface typical of TIPS particles.
- the surface of both sets of particles show deposits of amorphous material that is most likely to comprise the loaded precursor chemical active ingredient.
- a large pore was also visible on the surface of many of the micro-particles, which is also a characteristic feature of TIPS micro- and nano-particles.
- the precursor chemical is also encapsulated by the PLGA carrier, which is contained within the particles in a dry form, the solvents having been removed by the freeze-drying. It is desirable that the solvents used in the manufacturing process are removed or only minimally present as they can increase the toxicity of the particles.
- the TIPS preparation method tends to minimise and even eliminate solvent residues and also has the advantage of giving a greater control over porosity of the micro- and nano-particles, which also determines the controlled release time of the precursor chemical from the particle.
- Micro- and nano-particles encapsulating a TAED acetyl donor using acetonitrile as a solvent for the TAED may also be prepared by a similar TIPS process.
- the particles encapsulating sodium percarbonate and urea hydrogen peroxide described above were both used to test their capability in producing a change in pH of ultrapure water with an initial pH of 6.01 over a seven day test period.
- Samples of the particles were each placed into 2 ml polypropylene screw-cap microtubes and the ultrapure water was added to produce a final concentration of 20 mg micro- and nano-particles per 1 ml water.
- the particles were mixed by vortexing for 10 seconds before being incubated at 23°C.
- the pH of the samples was measured at pre-determined intervals. Each measurement was recorded after a pH electrode had been inserted into the sample for 2 minutes. The results are shown in Figs. 5 and 6 , the measurements being derived from four replicate samples with mean data being plotted showing standard error of mean.
- the change in pH observed following incubation of the particles indicates that the precursor chemicals are capable of sustained release from the particles to produce a therapeutic agent in accordance with the invention over a prolonged period as the particles degrade.
- the release occurs as the encapsulating polymer degrades, which in the case of a PLGA polymer is via hydrolysis. It is expect that the release kinetics (rate and duration) can be modified by adjusting the composition of the polymer used to manufacture the micro- and nano-particles.
- the invention is not limited to the use of poly(lactic-co-glycolic acid) (PLGA) - based micro- and nano-particles. Micro- and nano-particles using a variety of synthetic and natural polymers may be utilised.
- polymers examples include poly(allylamine)hydrochloride, poly(diallylmethylammonium chloride), polyethylenimine (PEI), polyvinyl pyrollidone, poly L ornithine, poly L arginine, protamines, chitosan, alginates, polystyrene sulphonate, poly(acrylic acid), poly(methacrylic acid), polyvinylsulfonate, poly phosphoric acid, poly L glutamic acid, alginates, and dextran sulphate.
- Nanomicellular carriers may also be made, for example, from polyethylene oxide/polypropylene oxide diblock and triblock copolymers, phospholipid or other surface active agents. Such carriers may be used in place or in addition to other micro- or nano-particle carriers.
- the carriers may also be treated with secondary processes such as treatment with polyethylene glycol, usually styled PEGylation, to protect the particle in the physiological milieu and, for example, to give extended circulation time in the bloodstream.
- the carriers may be treated with targeting ligands in order to provide enhanced target specificity.
- the carriers may be targeted by a biosensor such as a monoclonal antibody.
- the invention therefore combines well researched and widely used high level environmental antimicrobial agents and their biologically inert precursors encapsulated within a targeted micro- or nano-scale carrier.
- the precursor chemical or chemicals are sheltered from the immune responses of the host and prevented from causing unacceptable damage or side effect to the host tissues.
- the invention provides a therapeutically safe and effective means of targeting and killing infecting microorganisms, including multiple drug resistant organisms, and is capable of targeting a variety of body sites, including the bloodstream, the lungs, the liver, the kidneys, the gut, the urinary tract and the dermal layers.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1405874.7A GB201405874D0 (en) | 2014-04-01 | 2014-04-01 | A therapeutic agent for use in the treatment of infections |
GBGB1415063.5A GB201415063D0 (en) | 2014-04-01 | 2014-08-26 | A therapeutic agent for use in the treatment of infections |
EP15714598.8A EP3125874B1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
PCT/GB2015/000100 WO2015150722A1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15714598.8A Division EP3125874B1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3848022A1 EP3848022A1 (en) | 2021-07-14 |
EP3848022B1 true EP3848022B1 (en) | 2023-06-07 |
EP3848022C0 EP3848022C0 (en) | 2023-06-07 |
Family
ID=50737835
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15714598.8A Active EP3125874B1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
EP20215977.8A Active EP3848022B1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15714598.8A Active EP3125874B1 (en) | 2014-04-01 | 2015-03-24 | A therapeutic agent for use in the treatment of infections |
Country Status (16)
Country | Link |
---|---|
US (2) | US9913805B2 (zh) |
EP (2) | EP3125874B1 (zh) |
JP (1) | JP6573286B2 (zh) |
KR (2) | KR102359855B1 (zh) |
CN (1) | CN106456557B (zh) |
AU (1) | AU2015242495B2 (zh) |
CA (1) | CA2943431C (zh) |
DK (1) | DK3125874T3 (zh) |
ES (2) | ES2953755T3 (zh) |
GB (3) | GB201405874D0 (zh) |
IL (1) | IL247969B (zh) |
MX (1) | MX2016012757A (zh) |
NZ (1) | NZ724298A (zh) |
SG (2) | SG11201608093WA (zh) |
WO (1) | WO2015150722A1 (zh) |
ZA (1) | ZA201606387B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201405874D0 (en) * | 2014-04-01 | 2014-05-14 | Aga Nanotech Ltd | A therapeutic agent for use in the treatment of infections |
CN107281220B (zh) * | 2016-03-31 | 2020-02-14 | 中国科学院上海硅酸盐研究所 | 一种介孔氧化硅基活性氧(ros)放疗增敏剂及其制备方法 |
CN106860032B (zh) * | 2016-10-25 | 2021-04-09 | 咏达生医材料股份有限公司 | 一种气态皮肤供氧美白产品及其应用 |
JP2019194162A (ja) * | 2018-05-01 | 2019-11-07 | ツァ ギャリー | 肌の酸素供給による美白及び加熱機能を備えた通気性材料 |
GB2592911B (en) * | 2020-02-28 | 2023-06-28 | Aga Nanotech Ltd | A plasma-activatable wound dressing for treatment of infections |
GB202005556D0 (en) | 2020-04-16 | 2020-06-03 | Aga Nanotech Ltd | Covid face mask |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908614A (en) * | 1995-08-15 | 1999-06-01 | Montgomery; Robert Eric | Peroxidase-activating oral compositions |
ES2249856T3 (es) * | 1999-07-02 | 2006-04-01 | Cognis Ip Management Gmbh | Microcapsulas - iv. |
AU4477001A (en) * | 2000-04-18 | 2001-10-30 | Peptron Inc. | Injectable sustained release pharmaceutical composition and processes for preparing the same |
KR100342746B1 (ko) * | 2000-06-27 | 2002-07-03 | 김찬화 | 인슐린의 방출제어제제 및 그 방법 |
GB0411304D0 (en) * | 2004-05-21 | 2004-06-23 | Fellows Adrian N | An antimicrobial composition |
US20060088498A1 (en) * | 2004-10-27 | 2006-04-27 | Truox, Inc. | Anti-microbial composition using in-situ generation of an oxidizing agent |
EP1919507A2 (en) * | 2005-08-04 | 2008-05-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
KR20070071225A (ko) * | 2005-12-29 | 2007-07-04 | 애경산업(주) | 치아 미백용 조성물 |
GB0711952D0 (en) * | 2007-06-20 | 2007-08-01 | King S College London | Microspheres |
US20110218140A1 (en) * | 2008-02-25 | 2011-09-08 | Gonsalves Kenneth E | Biodegradable therapeutic nanoparticles containing an antimicrobial agent |
CA2946195A1 (en) * | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
US8969282B2 (en) * | 2009-02-05 | 2015-03-03 | American Sterilizer Company | Low odor, hard surface sporicide |
WO2010129309A2 (en) * | 2009-04-27 | 2010-11-11 | Premier Dental Products Compnay | Microencapsulated compositions and methods for tissue mineralization |
KR101136028B1 (ko) * | 2009-04-27 | 2012-04-18 | 한양대학교 산학협력단 | 다공성 마이크로스피어의 제조방법 |
NZ600269A (en) * | 2009-05-20 | 2014-02-28 | Dec Int Nz Ltd | Delivery device for treatment of mastitis |
US9187594B2 (en) * | 2010-02-09 | 2015-11-17 | The Regents Of The University Of Michigan | Nano-fibrous microspheres and methods for making the same |
ES2527193T3 (es) * | 2010-07-09 | 2015-01-21 | Innocore Technologies B.V. | Copolímeros multibloque segmentados de fases separadas biodegradables y liberación de polipéptidos biológicamente activos |
WO2012074588A2 (en) * | 2010-08-30 | 2012-06-07 | President And Fellows Of Harvard College | Shear controlled release for stenotic lesions and thrombolytic therapies |
GB201405874D0 (en) * | 2014-04-01 | 2014-05-14 | Aga Nanotech Ltd | A therapeutic agent for use in the treatment of infections |
-
2014
- 2014-04-01 GB GBGB1405874.7A patent/GB201405874D0/en not_active Ceased
- 2014-08-26 GB GBGB1415063.5A patent/GB201415063D0/en not_active Ceased
-
2015
- 2015-03-24 SG SG11201608093WA patent/SG11201608093WA/en unknown
- 2015-03-24 KR KR1020167030614A patent/KR102359855B1/ko active IP Right Grant
- 2015-03-24 CN CN201580018976.4A patent/CN106456557B/zh active Active
- 2015-03-24 KR KR1020227003691A patent/KR102482597B1/ko active IP Right Grant
- 2015-03-24 NZ NZ724298A patent/NZ724298A/en unknown
- 2015-03-24 WO PCT/GB2015/000100 patent/WO2015150722A1/en active Application Filing
- 2015-03-24 ES ES20215977T patent/ES2953755T3/es active Active
- 2015-03-24 EP EP15714598.8A patent/EP3125874B1/en active Active
- 2015-03-24 AU AU2015242495A patent/AU2015242495B2/en active Active
- 2015-03-24 SG SG10201801524PA patent/SG10201801524PA/en unknown
- 2015-03-24 GB GB1617053.2A patent/GB2538923B/en active Active
- 2015-03-24 JP JP2017503081A patent/JP6573286B2/ja active Active
- 2015-03-24 MX MX2016012757A patent/MX2016012757A/es active IP Right Grant
- 2015-03-24 ES ES15714598T patent/ES2855985T3/es active Active
- 2015-03-24 EP EP20215977.8A patent/EP3848022B1/en active Active
- 2015-03-24 US US15/126,511 patent/US9913805B2/en active Active
- 2015-03-24 CA CA2943431A patent/CA2943431C/en active Active
- 2015-03-24 DK DK15714598.8T patent/DK3125874T3/da active
-
2016
- 2016-09-15 ZA ZA2016/06387A patent/ZA201606387B/en unknown
- 2016-09-22 IL IL247969A patent/IL247969B/en active IP Right Grant
-
2018
- 2018-01-18 US US15/874,552 patent/US10933026B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3848022B1 (en) | A therapeutic agent for use in the treatment of infections | |
Lakshminarayanan et al. | Recent advances in the development of antimicrobial nanoparticles for combating resistant pathogens | |
AU2015315108B2 (en) | Antimicrobial and biologically active polymer composites and related methods, materials and devices | |
Su et al. | Biofilms: formation, research models, potential targets, and methods for prevention and treatment | |
Dekina et al. | Gelatin/carboxymethyl cellulose mucoadhesive films with lysozyme: Development and characterization | |
Li et al. | Biguanide-derived polymeric nanoparticles kill MRSA biofilm and suppress infection in vivo | |
Kasimanickam et al. | Prevention and treatment of biofilms by hybrid-and nanotechnologies | |
KR20080090489A (ko) | 살균제 조성물 및 그 사용 방법 | |
Quijia et al. | Metal-organic frameworks for diagnosis and therapy of infectious diseases | |
Prabhu et al. | Nanocarriers for effective topical delivery of anti-infectives | |
Sofokleous et al. | Sustained antimicrobial activity and reduced toxicity of oxidative biocides through biodegradable microparticles | |
Zhang et al. | Nanocarriers for combating biofilms: Advantages and challenges | |
Platon et al. | Erythromycin formulations—a journey to advanced drug delivery | |
Mahavir et al. | Application of nanostructures in antimicrobial therapy | |
Kanth et al. | Recent advancements and perspective of ciprofloxacin-based antimicrobial polymers | |
Panthi et al. | Liposomal drug delivery strategies to eradicate bacterial biofilms: Challenges, recent advances, and future perspectives | |
US20190060270A1 (en) | Disinfectant agent | |
Pourmadadi et al. | Organic and inorganic nanoparticles as emerging nanoplatforms for cephalexin delivery | |
Jayapalan et al. | Advances of antimicrobial nanosystems and their application in pharmaceuticals | |
Singh et al. | Limiting Antibiotic-Resistant Bacteria Using Multifunctional Nanomaterials | |
Onuigbo et al. | Chitosan-based nanoparticles sustenance and potentiation of the antibacterial effect of ampicillin against drug resistance among strains of Escherichia coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3125874 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40052395 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220113 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220502 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/00 20060101ALI20221031BHEP Ipc: A61K 33/40 20060101ALI20221031BHEP Ipc: A61K 31/327 20060101ALI20221031BHEP Ipc: A61K 9/51 20060101ALI20221031BHEP Ipc: A61K 9/50 20060101AFI20221031BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20221209 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3125874 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1572778 Country of ref document: AT Kind code of ref document: T Effective date: 20230615 Ref country code: DE Ref legal event code: R096 Ref document number: 602015084144 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20230614 |
|
RAP4 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: AGA NANOTECH LTD |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230707 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230907 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2953755 Country of ref document: ES Kind code of ref document: T3 Effective date: 20231115 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015084144 Country of ref document: DE |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 10 Effective date: 20240301 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240312 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240301 Year of fee payment: 10 |
|
26N | No opposition filed |
Effective date: 20240308 |